Goldman Sachs reiterates Summit Therapeutics stock rating on AstraZeneca deal

Goldman Sachs has reaffirmed a Buy rating and set a $41 price target for Summit Therapeutics (SMMT) following the firm's announcement of a strategic partnership with AstraZeneca. Despite a recent 10% drop in the stock's value to $15.48 and a $12.35 billion market cap, the company revealed agreements for a $2 billion equity investment and clinical collaborations with AstraZeneca.

These collaborations will evaluate ivonescimab and antibody drug conjugate sonesitatug vedotin in gastrointestinal cancers, as well as include additional ivonescimab combination trials with AstraZeneca medicines. The partnership will provide Summit Therapeutics with an extended cash runway, accompanied by around 10.6% dilution, due to shared development costs and retained commercial rights for their respective molecules.

Summit Therapeutics currently holds a strong current ratio of 6.96, ensuring liquid assets significantly outweigh short-term obligations—a significant advantage as it funds ongoing clinical trials. Analyst Satoru Ogawa of Goldman Sachs highlighted the non-exclusive nature of the partnership, granting access to AstraZeneca's antibody drug conjugate pipeline and enabling optimal ivonescimab combinations for individual cancers.

Summit Therapeutics maintains strategic partnerships with Revolution Medicines, GSK, and Arcus Biosciences for various oncology projects, with its global Phase 3 HARMONi-3 ivonescimab study in frontline non-small cell lung cancer remaining a primary focus.